Cadence proposes $75M underwritten public offering of common stock

Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced its intention to offer and sell $75 million worth of shares of its common stock in an underwritten public offering.  Cadence also expects to grant to the underwriters for the offering a 30-day option to purchase additional shares of common stock to cover over-allotments, if any.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  

Deutsche Bank Securities Inc. is acting as sole book-running manager and Leerink Swann LLC is acting as lead manager for the offering.